C07D311/54

ACTIVE HETEROGENIZED PALLADIUM-BRIDGED-NHC CATALYSTS FOR CARBONYLATIVE SONOGASHIRA COUPLING REACTIONS
20220411451 · 2022-12-29 ·

This disclosure relates to solid-supported bridged Pd(II)—N-heterocyclic carbene catalysts, methods of preparing the catalysts, and methods of using the catalysts in carbonylative Sonogashira coupling reactions.

ACTIVE HETEROGENIZED PALLADIUM-BRIDGED-NHC CATALYSTS FOR CARBONYLATIVE SONOGASHIRA COUPLING REACTIONS
20220411451 · 2022-12-29 ·

This disclosure relates to solid-supported bridged Pd(II)—N-heterocyclic carbene catalysts, methods of preparing the catalysts, and methods of using the catalysts in carbonylative Sonogashira coupling reactions.

PTPRD INHIBITORS AND USES THEREOF

Disclosed are small molecule PTPRD inhibitors and uses thereof. Methods of using the PTPRD inhibitors include methods of treating, preventing, or delaying the progression of a disorder responsive to PTPRD inhibition, including for example nicotine dependence, addiction, obesity, metabolic syndrome, and substance-use disorders such as stimulant-use disorders and opioid-use disorders.

PTPRD INHIBITORS AND USES THEREOF

Disclosed are small molecule PTPRD inhibitors and uses thereof. Methods of using the PTPRD inhibitors include methods of treating, preventing, or delaying the progression of a disorder responsive to PTPRD inhibition, including for example nicotine dependence, addiction, obesity, metabolic syndrome, and substance-use disorders such as stimulant-use disorders and opioid-use disorders.

Compounds and compositions for treating conditions associated with NLRP activity
11597706 · 2023-03-07 · ·

In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured: Formulae (I) and (II), wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein. ##STR00001##

Compounds and compositions for treating conditions associated with NLRP activity
11597706 · 2023-03-07 · ·

In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured: Formulae (I) and (II), wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein. ##STR00001##

Photocatalyst-free, light-induced carbon-sulfur cross-coupling methods

In one aspect, the invention provides a method of promoting a carbon-sulfur bond forming reaction. In certain embodiments, the reaction comprises cross-coupling of a(n) (hetero)aryl halide with a thiol to form the carbon-sulfur bond, wherein the method is promoted by light irradiation in the absence of a photocatalyst. In other embodiments, the cross-coupling reaction can be promoted through visible light irradiation, including sunlight.

Photocatalyst-free, light-induced carbon-sulfur cross-coupling methods

In one aspect, the invention provides a method of promoting a carbon-sulfur bond forming reaction. In certain embodiments, the reaction comprises cross-coupling of a(n) (hetero)aryl halide with a thiol to form the carbon-sulfur bond, wherein the method is promoted by light irradiation in the absence of a photocatalyst. In other embodiments, the cross-coupling reaction can be promoted through visible light irradiation, including sunlight.

Compounds and compositions for treating conditions associated with NLRP activity
11339136 · 2022-05-24 · ·

In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein. ##STR00001##

Compounds and compositions for treating conditions associated with NLRP activity
11339136 · 2022-05-24 · ·

In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein. ##STR00001##